LY-456219: Difference between revisions
CSV import |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:LY-456219_Structure.svg|LY-456219 Structure | |||
</gallery> | |||
Latest revision as of 00:23, 17 March 2025
LY-456219 is a chemical compound that was developed by Eli Lilly and Company. It is a selective serotonin reuptake inhibitor (SSRI) and was developed for the treatment of depression and anxiety disorders. However, it was discontinued in the early stages of development and is not currently available for medical use.
History[edit]
LY-456219 was developed by Eli Lilly and Company, a pharmaceutical company based in the United States. The compound was part of a series of SSRIs that were being developed by the company during the late 1990s and early 2000s. However, the development of LY-456219 was discontinued in the early stages of clinical trials. The reasons for the discontinuation are not publicly available, but it is common for drugs to be discontinued due to issues with safety, efficacy, or commercial viability.
Pharmacology[edit]
As an SSRI, LY-456219 works by inhibiting the reuptake of serotonin in the brain. This increases the amount of serotonin available in the synaptic cleft, which can help to alleviate symptoms of depression and anxiety. However, the exact pharmacological profile of LY-456219 is not well known, as it was discontinued before extensive studies could be conducted.
Potential Uses[edit]
While LY-456219 is not currently available for medical use, SSRIs in general are used for a variety of psychiatric conditions. These include depression, anxiety disorders, obsessive-compulsive disorder (OCD), panic disorder, and post-traumatic stress disorder (PTSD). However, it is unclear whether LY-456219 would have been effective for these conditions, as it was discontinued before clinical trials could be completed.
